CD75 Inhibitors

CD75 inhibitors comprise various compounds that indirectly modulate the function of CD75 by influencing the glycosylation and sialylation processes in cells. These compounds target different stages of the glycosylation pathway, thereby potentially affecting the activity of CD75, which is involved in the addition of sialic acid to glycoproteins and glycolipids. Compounds such as Kifunensine, Swainsonine, Benzyl-α-GalNAc, Tunicamycin, Castanospermine, Deoxynojirimycin, and Deoxymannojirimycin inhibit different enzymes involved in the glycosylation process. For instance, Kifunensine and Swainsonine inhibit mannosidase enzymes, altering the glycosylation pattern, which could influence the substrates available for CD75. Benzyl-α-GalNAc and Tunicamycin impact O-glycosylation and N-linked glycosylation, respectively, potentially affecting the glycoprotein structures and functions related to CD75's activity. Additionally, compounds like PDMP, NB-DNJ, and Brefeldin A target specific aspects of glycoprotein processing and Golgi apparatus function. PDMP inhibits glucosylceramide synthase, affecting glycosphingolipid synthesis, while NB-DNJ is a glucosidase inhibitor, both potentially influencing glycoprotein processing pathways involving CD75. Brefeldin A disrupts Golgi apparatus function, which is crucial for glycoprotein modification, thereby possibly impacting CD75's role in sialylation.